Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TOP1 | P11387 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487939 | 0.86 | LMNA (0.60) | LMNACHRM1TOP1 | |
| SCHEMBL17338534 | 0.86 | LMNA (0.73) | LMNACHRM1GAAHTT | |
| SCHEMBL2487513 | 0.84 | LMNA (0.84) | LMNACHRM1 | |
| SCHEMBL14584210 | 0.80 | NPSR1 (0.58) | LMNAGAAHTT | |
| SCHEMBL9028399 | 0.79 | LMNA (1.00) | LMNACHRM1 | |
| SCHEMBL31554247 | 0.79 | LMNA (1.00) | LMNACHRM1 | |
| SCHEMBL30125372 | 0.78 | LMNA (0.76) | LMNACHRM1 | |
| SCHEMBL19147378 | 0.78 | MEN1 (0.55) | LMNAGAAHTT | |
| SCHEMBL2490004 | 0.76 | CHRM1 (0.54) | LMNACHRM1 | |
| SCHEMBL21999706 | 0.76 | LMNA (0.69) | LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | claimed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | claimed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | claimed |
| EP-2037739-A2 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck & Co., Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008002621-A2 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2008-01-03 | — | — | WO | claimed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| WO-2008002621-A2 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | CHRM1, OPRL1, MTNR1A | LMNA 3254/4885CHRM1 1/4885GAA 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.